// App-Quantinova.ai

: Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

Researchers

Presenter

  • Jad Othman

Principal Investigators

  • Katya Mokretar

  • Adam Ivey

  • Michael James Austin

  • Anne-Louise Latif

  • Charles Crawley

  • Mariam Amer

  • Francesca Crolla

  • Joe W Cross

  • Raymond Dang

  • Chun Yew Fong

  • Sofia Galli

  • Paolo Gallipoli

  • Francesca L Hogan

  • Pallavi Kalkur

  • Anjum Khan

  • Pramila Krishnamurthy

  • John Laurie

  • Scott R. Marshall

  • Vidhya Murthy

  • Sateesh K. Nagumantry

  • Srinivas Pillai

  • Nicola Potter

  • Tom Taylor

  • Rui Zhao

  • Andrew H Wei

  • Richard Dillon

Medical Centers

  • Peterborough City Hospital, Peterborough, United Kingdom

  • Nottingham University Hospital, Nottingham, United Kingdom

  • Worthing Hospital, Worthing, United Kingdom

  • James Cook University Hospital, Middlesbrough, GBR

  • Molecular Pathology, The Alfred Hospital, Melbourne, Australia

  • Musgrove Park Hospital, Taunton, GBR

  • Addenbrooke's Hospital, Cambridge, GBR

  • King's College Hospital, London, United Kingdom

  • Department of Haematology, Queen Elizabeth University Hospital, Glasgow, United Kingdom

  • University Hospital of Wales, Cardiff, GBR

  • The Alfred Hospital and Monash University, Melbourne, Australia

  • Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

  • Cancer Genetics, Viapath, London, GBR

  • Department of Pathology, Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, Australia

  • St James's Institute of Oncology, The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Southend Hospital, Southend, GBR

  • University Hospital Bristol, Bristol, GBR

  • City Hospitals Sunderland NHS Trust, Sunderland, GBR

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Royal Stoke University Hospital, University Hospital of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom

  • Centre for Clinical Haematology, University Hospitals Birmingham, Birmingham, United Kingdom

  • Frimley Park Hospital, London, GBR

  • Department of Medical and Molecular Genetics, King's College London, London, UNITED KINGDOM

  • Torbay Hosital, Torquay, GBR

  • University Hospital Southampton, Southampton, United Kingdom

  • Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, Australia

Locations

  • United Kingdom

  • Australia

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Nucleophosmin 1

Drug/Treatment

  • Venetoclax

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved